For all press and media enquiries please contact mediarelations@chiesi.com
- Following the recent European Commission Authorization, FDA approves PRX-102 for the treatment of Fabry disease - PARMA, BOSTON and CARMIEL, Israel, May 10, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people…
- PEGylated enzyme replacement therapy designed to provide a long half-life - PARMA, Italy, BOSTON and CARMIEL, Israel, May 5 th, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases,…
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland and Boston MA, April 12, 2023 – Chiesi Farmaceutici S.p.A. (“Chiesi”), an international, research-focused…
Turnover at €2 billion 749 million, with growth of 13.6% over 2021; The European market remains at the center, with significant international development; The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare diseases) 12% and Care…
Chiesi Group and Affibody will collaborate closely to develop novel Affibody ® molecules as innovative treatments for respiratory diseases. This agreement expands Chiesi’s comprehensive R&D program in respiratory diseases with high unmet medical needs. Affibody will receive an upfront payment,…
International Call for ideas for the regeneration of the Chiesi pharmaceutical group's historic industrial site at Via Palermo, Parma March 1 st – April 30 th, 2023 Starting today, Wednesday 1 March, Restore to Impact - The next healthcare landmark for innovation and future-oriented competences, an…
- European Commission decision anticipated in beginning of May 2023 - PARMA, Italy and BOSTON and CARMIEL, Israel, February 24 th, 2023 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases,…
Company also presents insights from the SPARKLE registry in alpha-mannosidosis that highlight a delay in diagnosis, identify the most frequent genetic MAN2B1 variant in enrolled participants, and report on real-world clinical profiles. BOSTON, February 24, 2023 – Chiesi Global Rare Diseases, a…
First and only enzyme replacement therapy for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients; Ultra-rare progressive disease presents with wide range of symptoms. BOSTON, February 20, 2023 – Chiesi Global Rare Diseases, a business…
You are leaving the Chiesi Corp site to access another Chiesi site. Regulatory constraints and medical practices, as well as the information published on the site you are about to visit, may change from one country to another and may not comply with current Italian legislation on the subject.
You are about to leave our website and access an external site. By continuing, you agree to leave our site.
